Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2025 12:05 ET | Source: Tonner Drones

Tonner Drones erhält Patent für Inhibitor in den USA

Tonner Drones erhält Patent für Inhibitor in den USA Schiltigheim, 23. April 2025, 18:00 Uhr, Tonner Drones gibt erfreut bekannt, dass sein Patent für den Inhibitor in den USA erteilt wurde. Tonner...
April 23, 2025 12:05 ET | Source: Tonner Drones

Tonner Drones Obtains Patent For Inhibitor In The United States

Tonner Drones Obtains Patent For Inhibitor In The United States Schiltigheim, April 23th 2025 18:00, Tonner Drones is pleased to announce that its patent for the Inhibitor is granted in the USA. ...
April 23, 2025 12:05 ET | Source: Tonner Drones

Tonner Drones obtient un brevet pour un inhibiteur aux États-Unis

Tonner Drones obtient un brevet pour un inhibiteur aux États-Unis Schiltigheim, le 23 avril 2025 18h00, Tonner Drones a le plaisir d'annoncer que son brevet pour l'Inhibiteur est accordé aux USA. ...
September 26, 2024 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

BOTHELL, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in the multiple-ascending dose (MAD)...
November 08, 2023 08:05 ET | Source: BioTech Breakthrough

K36 Therapeutics Named “Overall BioPharma Startup of the Year” By BioTech Breakthrough

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program...
December 16, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors

PHILADELPHIA, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today further progress on developing Ampligen® (rintatolimod)...
January 28, 2013 08:30 ET | Source: MolecularMD

MolecularMD Corp. Obtains Exclusive License to LKB1 Uses in Non-Small Cell Lung Cancer

PORTLAND, OR--(Marketwire - Jan 28, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...